- Blum is showing operational stabilization with rising revenue, improved gross margin, and sharply lower SG&A, but continuing operations remain loss-making and cash-flow negative.
- Reported FY2024 net income was largely driven by one-time gains from divestitures and discontinued operations rather than core profitability.
- Liquidity is the central risk, with cash under $0.4 million, a working-capital deficit above $20 million, and management flagging substantial doubt about going concern.
- Growth via stock-based acquisitions and management deals may add sales but increases dilution and balance-sheet strain amid margin pressure and 280E tax overhang.
Read More
The headline “Blum Capital on Losing Streak” suggests a narrative of continued decline. In fact, the issues appear less about a linear fall and more about a critical inflection point where operational improvements clash with financing strain and regulatory drag.
What’s working: Blum has executed a large-scale cleanup: expired liabilities addressed (via subsidiary bankruptcies and litigation settlements), unprofitable retail locations divested, SG&A cut significantly, and cost base restructured. These steps have yielded tangible improvements. For example, in Q1 2025, revenues rose ~26% year-over-year to $2.24 million, EBITDA turned slightly positive ($57,000), and adjusted EBITDA loss narrowed substantially. Similarly, in Q2, revenue increased to $3.48 million and operating expenses dropped 69% y/y, though net loss widened due to margin compression and expenses associated with new store ramp.
What remains dangerous: Cash and liquidity are critical failure points. With only ~$0.37–$0.39 million in cash as of mid-2025, and current assets covering just ~8% of current liabilities, Blum’s runway is extremely limited absent raising substantial capital or selling assets. Additionally, its working capital deficit has deepened—from under $7 million as of December 2024 to over $20 million by mid-2025.
Structural and regulatory risks: A major overhang remains the 280E rule—federal taxation of cannabis profitability—as liabilities under income tax payable have surged, and margins are under pressure from value-oriented retail models and price competition. Public policy shifts (rescheduling, federal reform) are essential tailwinds, but are uncertain.
Growth is capital expensive and dilutive: Bloom has added California dispensaries via acquisitions or management agreements, some of which are stock‐based or accompanied by promissory notes. These moves produce revenue gains (new stores expected to generate ~$12 million or more in annualized sales) but dilute existing shareholders and add to goodwill and liabilities without guaranteeing commensurate cash flow.
Strategic implications & open questions:
- Can newly acquired or managed stores reach operational contribution quickly enough to offset the cash burn and stabilize working capital?
- Will Blum be able to raise capital on acceptable terms, or will future financing result in prohibitive dilution or enforce tough covenants?
- How much of Blum’s improved financials depend on gains from asset sales or discontinued operations, and what is the baseline core performance absent those?
- Are regulatory reforms (federal tax law, rescheduling, or 280E reform) feasible or imminent enough to materially reshape margins and reduce liabilities?
- What risks might poor internal controls (which management has disclosed) pose in sustaining the improvements or in external perception/financing?
Supporting Notes
- Revenue growth: Q1 2025 revenue was $2.24 million vs $1.78 million in Q1 2024, up ~26% y/y; gross margin in Q1 improved from 45% y/y to 53%.
- Expense reduction: Operating expenses in Q2 2025 were ~$2.5 million, a ~69% drop from ~$8 million in Q2 2024.
- EBITDA: Q1 2025 positive EBITDA of $57,000, compared to a loss of ~$3.0 million in Q1 2024; Adjusted EBITDA loss narrowed from $3.3 million in Q1 2024 to $0.4 million in Q1 2025.
- Net loss: Despite improvements, net loss from continuing operations was $0.6 million in Q1 2025 and widened to $1.9 million in Q2 2025; Q2 2024 had a net income of $7.3 million, which included major one-time gains.
- Balance sheet: Cash & equivalents dropped from ~$1.04 million at end 2024 to ~$0.37 million by June 30, 2025; working capital deficit deepened from ~$6.8 million to ~$20.8 million in same period.
- Assets and liabilities: Total assets increased to ~$39-46 million via acquisitions; total liabilities rose correspondingly to ~$45-52 million, producing a stockholders’ deficit of ~$9-12 million.
- Going concern: Management disclosed “substantial doubt” about ability to continue operations over next 12 months due to liquidity risk.
- Dilutive financing: Capital raises in 2025 include unsecured promissory notes, stock issuances, warrants; a recent transaction (Mt. Tam Ventures II) valued at $3.9 million involves significant stock issuance ($1.90/share).
- Dependence on non-core gains: Fiscal year 2024 net income of $33.1 million came after liability reduction and gains in discontinued operations; adjusted EBITDA from continuing operations still showed a $10.9 million loss.